Charles River Laboratories EBIT 2010-2024 | CRL

Charles River Laboratories EBIT for the quarter ending December 31, 2024 was $-0.168B, a 226.15% decline year-over-year.

  • Charles River Laboratories 2024 EBIT was 0.227B, a 63.17% decline from 2023.
  • Charles River Laboratories 2023 EBIT was 0.617B, a 5.18% decline from 2022.
  • Charles River Laboratories 2022 EBIT was 0.651B, a 10.36% increase from 2021.

EBIT can be defined as earnings before interest and taxes.

Charles River Laboratories EBIT 2010-2024 | CRL

  • Charles River Laboratories 2024 EBIT was 0.227B, a 63.17% decline from 2023.
  • Charles River Laboratories 2023 EBIT was 0.617B, a 5.18% decline from 2022.
  • Charles River Laboratories 2022 EBIT was 0.651B, a 10.36% increase from 2021.

EBIT can be defined as earnings before interest and taxes.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$150.2B
Elevance Health (ELV)$90.6B
CVS Health (CVS)$82.1B
Cencora (COR)$47.2B
DiDi Global (DIDIY)$23.3B
Natera (NTRA)$22.2B
ICON (ICLR)$16.7B
BioMerieux (BMXMF)$14.1B
Doximity (DOCS)$14B
Revvity (RVTY)$14B
Viatris (VTRS)$13.2B
Solventum (SOLV)$12.9B
Avantor (AVTR)$11.9B
CochLear (CHEOY)$11.3B
Medpace Holdings (MEDP)$10.5B
EUROFINS SCIENT (ERFSF)$9.8B
HealthEquity (HQY)$9.7B
Sonic Healthcare (SKHHY)$8.7B
Amplifon S.p.A (AMFPF)$6.2B
Bausch + Lomb (BLCO)$5.6B
Organon (OGN)$4B
Sotera Health (SHC)$3.8B
BrightSpring Health Services (BTSG)$3.6B
Surgery Partners (SGRY)$3.3B
Concentras Parent (CON)$3B
GeneDx Holdings (WGS)$2.8B
Alignment Healthcare (ALHC)$2.8B
Teladoc Health (TDOC)$2.2B
Ardent Health Partners (ARDT)$2.1B
Progyny (PGNY)$2B